Activity Overview
This online, on-demand virtual symposium brings together renowned experts HR+/HER2– breast cancer. In this educational program, these experts review recent key findings and discuss their potential implications for community oncologists. The program features dynamic discussions, practical insights, and the latest data from pivotal clinical trials. The format is designed to provide actionable, evidence-based guidance specifically tailored to help community-based oncology professionals seamlessly integrate these advances into their everyday practice to optimize patient care.
This educational activity is an archive of the live presentation held on October 2, 2026.
Target Audience
This educational program is directed toward community-based medical oncologists, surgeons, advanced practice providers, nurses, and other health care professionals involved in the treatment of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Develop biomarker-based diagnostic approaches to assess HR+/HER2-advanced breast cancer progression and identify optimal treatment options
- Assess clinical trial data for current and emerging agents for HR+/HER2– breast cancer and impact on the treatment paradigm for treatment plans
- Implement shared decision-making strategies to optimize adverse event management and enhance treatment adherence in clinical practice
Komal Jhaveri, MD, FACP
Associate Attending Physician, Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Evelyn H. Lauder Breast and Imaging Center
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: Arvinas, AstraZeneca, BeOne Therapeutics, Bicycle Therapeutics, Blueprint Medicines, Bridge Bio Oncology, ConcertAI, Daiichi Sankyo, Eisai, Genentech, Gilead, Halda Therapeutics, Lilly/Loxo Oncology, Merck Pharmaceuticals, Mersana, Natera, Novartis, Olema Pharmaceuticals, Pfizer, Precede Biosciences, RayzeBio, Relay Pharmaceuticals, Scorpion Therapeutics, Zymeworks; Honoraria: Aptitude Health, Curio Sciences; Research Funding (paid to institution): AstraZeneca, Bicycle Therapeutics, Blueprint Medicines, Bridge Bio Oncology Therapeutics, Eisai, Genentech, Gilead, Lilly/Loxo Oncology, Merck Pharmaceuticals, Novartis, Pfizer, PUMA Biotechnology, RayzeBio, Scorpion Therapeutics, Zymeworks
Ruta D. Rao, MD
Professor of Medicine
Director, Coleman Foundation Comprehensive Breast Cancer Clinic
Medical Director, RUSH University Cancer Center
Chicago, IL
Disclosures: Consultant/Advisor: DSI, Genentech, Lilly, Pfizer, TerSera
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.